Oncodesign Announces a Capital Increase Reserved for the Company’s Management Committee

Christel Deskins

Alignment of interests between Oncodesign’s Management and shareholders Reserved capital increase for a total of €300,000 Allocation of free shares and stock options to the Company’s Management Committee Regulatory News: ONCODESIGN (Paris:ALONC) (ALONC – FR0011766229), a biopharmaceutical group specialized in precision medicine, today announces the launch of a reserved capital […]